RD Saúde

What RD Saúde does

RD Saúde (legal name Raia Drogasil S.A.) is Brazil's largest pharmaceutical retail group, publicly listed on the Novo Mercado segment of B3 under ticker RADL3, headquartered in São Paulo. The company operates an integrated health ecosystem anchored by two flagship pharmacy chains — Raia (founded 1905, present in the Southeast and South) and Drogasil (founded 1935, present across the Southeast, Midwest, Northeast and North) — totalling 3,547 physical pharmacies in 663 municipalities across all Brazilian states, serving 51.7 million active customers with prescription medicines, OTC products, dermocosmetics, personal care, beauty and private-label brands (Needs, Natz, B-Well, Caretech, Nutri Good).

The group's underlying technology platform combines 15 distribution centers plus one logistics hub — including a modern robotic-assisted facility in Viana (ES) that increased productivity by 75% and reduced operational errors by 99% — with an e-commerce channel (rd.com.br) that delivered R$11.3B in 2025 revenue (25.7% of retail) and fulfilled 97% of digital orders in under one hour. Layered on top of the physical and digital retail is the Vitat online health and well-being platform (58.6 million users, 266,000 in habit programs), plus digital health subsidiaries Cuco Health, Healthbit, Amplimed and Manipulê, the Impulso retail media network, the Univers loyalty program, RD Saúde Ventures (corporate venture capital), and a 23.61% stake in Labi Exames and a 33.3% stake in the Stix loyalty JV with GPA. Family-controlled governance under the Pipponzi family, with Marcilio D'Amico Pousada as CEO, has enabled sustained long-term digital investment (administrative expenses grew from 13% to 30% of revenue during the digital pivot).

RD Saúde's business model is predominantly retail transaction-based: FY2025 gross revenue of R$47.6B (up 13.9% YoY) generated an adjusted EBITDA of R$3.4B (+12.8%) and adjusted net profit of R$1.3B, at a conservative 1.2x net debt/EBITDA. Revenue streams include core retail pharmacy sales, an e-commerce and marketplace channel, specialty pharmaceutical distribution (4Bio, divested to Profarma in 2026 for R$600M), private-label sales, the Farmácia Popular government-subsidized program across 1,015 pharmacies, the Vitat digital health platform, and exclusive distribution partnerships (e.g., Dr. Wolff Group's Alpecin and Bioniq brands). Distribution is essentially 100% domestic across Brazil's five regions, with exclusive and JV partnerships providing incremental international product access rather than geographic diversification.

Name

RD Saúde

Legal name

Raia Drogasil S.A.

Website

https://rdsaude.com.br

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

RD Saúde (Raia Drogasil S.A.) is Brazil's largest pharmaceutical retail group, operating 3,547 Raia and Drogasil pharmacies across 663 municipalities and serving 51.7 million active customers with prescription medicines, OTC products, dermocosmetics, and a growing digital health ecosystem (Vitat, e-commerce, retail media).

Ownership category

akta.pro rank

Product category

Retail Pharmacy

NAICS

Pharmacies and Drug Retailers (45611), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Retail-Drug Stores And Proprietary Stores (5912), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Retail & Community Pharmacies (Chain/Independent) (HLAFALAA)

akta.pro secondary industries

Health, Wellness & Pharmacy Marketplaces (CRAFABAF), 340B Program Administration & Contract Pharmacy Services (HLAFALAL), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Pharmaceutical retail
• Pharmacy chains
• Digital health platform
• Specialty pharmaceutical distribution
• E-commerce pharmacy

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices8 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Retail Pharmacy Sales: Core retail pharmacy business selling prescription medications, OTC products, perfumery, personal care, cosmetics, and dermocosmetics through Raia and Drogasil chains across 3,547 pharmacies. Revenue reached R$47.6 billion gross in 2025, representing the primary revenue stream.
2. Specialty Pharmaceutical Distribution (4Bio): High-complexity medication distribution through 4Bio subsidiary. Sold to Profarma in 2025/2026. LTM revenue of R$3.4 billion with 15% annual growth and net income of R$236.6 million at time of sale.
3. Digital Health Platform Services: Revenue from digital health platform (Vitat) connecting products, services, and solutions including online specialist consultations, appointment scheduling, and health programs. The platform had 58.6 million users in 2023.
4. Private Label / Exclusive Brands: Sale of proprietary brand products under exclusive labels including Needs, Natz, Bwell, Caretech, Nutri Good, and Caretech across categories including personal care, natural products, supplements, and medical equipment. Own brands grew 14.6% in 2023.
5. E-commerce and Marketplace: Online sales and third-party marketplace through rd.com.br, generating R$11.3 billion in e-commerce revenue in 2025 (25.7% of retail), plus R$5.1 billion through the marketplace of health and well-being products.
6. Farmácia Popular (Government Program): Participation in Brazil's Farmácia Popular government program across 1,015 pharmacies, offering essential medications at reduced or no cost to low-income populations.

Go-to-market motion1 record

Distribution channels7 records

Marketing channels10 records

Core offering

RD Saúde is Brazil's largest pharmaceutical retail company, operating 3,547 Raia and Drogasil pharmacies across all 663 municipalities, integrated with e-commerce (R$11.3 billion, 25.7% of retail), a third-party health-and-wellness marketplace (R$5.1 billion), and digital health services via the Vitat platform (58.6 million users). It also sells exclusive private-label brands (Needs, Natz, Bwell, Caretech, Nutri Good), operates specialty pharmaceutical distribution through the 4Bio subsidiary (being divested to Profarma for R$600 million), provides in-pharmacy health services such as vaccinations and rapid tests through Espaço Sua Saúde, and reaches low-income patients via Brazil's Farmácia Popular government program across 1,015 pharmacies.

Product overview

RD Saúde is Brazil's largest pharmaceutical retail group, operating an integrated health ecosystem built around two flagship pharmacy chains (Raia and Drogasil with 3,547 stores), a portfolio of exclusive private-label brands (Needs, Natz, Bwell, Caretech, Nutri Good), and a growing suite of digital health platforms and business solutions (Vitat, Cuco Health, Health Bit, Amplimed, Impulso retail media, Univers loyalty). The company also runs RD Saúde Ventures as its startup investment arm and Farol as a social-business initiative. Together, these offerings span physical retail, digital health engagement, corporate wellness management, pharmacy practice software, and retail media — unified under the goal of delivering integral health across the Brazilian population.

Differentiator

Problem solved

Functional benefit

Brands

• Univers: Benefits program of Raia and Drogasil pharmacies offering convenience to users.
• Espaço Sua Saúde
• Needs
• Natz
• B-Well
• Caretech
• Nutri Good
• Farol
• Raia + Drogasil Marketplace

Products and services

• Farmacías Raia e Drogasil RD Saúde's flagship pharmacy retail chains Raia (Southeast and South Brazil) and Drogasil (Southeast, Midwest, Northeast, and North Brazil), totalling 3,547 pharmacies across 663 municipalities as of 2025. The retail pharmacy network sells prescription medicines, OTC medications, perfumery, personal care, beauty, cosmetics, and dermocosmetics, serving 51.7 million active customers.
• E-commerce rd.com.br
• Raia + Drogasil Health and Well-being Marketplace
• Vitat
• Cuco Health
• Health Bit
• Amplimed
• Impulso
• Univers
• Needs (exclusive brand)
• Natz (exclusive brand)
• Bwell (exclusive brand)
• Caretech (exclusive brand)
• Nutri Good (exclusive brand)
• Farmácia Popular Program Participation

Quantifiable outcome

• Digital sales now represent nearly one-third (~30%) of total business, up from 1% in 2018.
• +6 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Profarma / Health VenturescoreOthers · 3 March 2026RD Saúde sold its wholly-owned subsidiary 4Bio Medicamentos (high-complexity medication distribution business) to Health Ventures, a unit of Grupo Profarma Distribuidora de Produtos Farmacêuticos SA, for R$600 million in a six-tranche payment structure (R$100M initial at closing, five annual R$100M installments adjusted by Brazil's CDI benchmark). The transaction is subject to CADE antitrust approval and buyer shareholder approval. RD Saúde retains rights to estimated R$120 million in ICMS tax assets with an expected R$60 million income tax gain.
• Dr. Wolff GroupcoreChannel Partner/ Reseller/ Distributor · 19 February 2025Exclusive distribution agreement with German family-owned Dr. Wolff Group (120 years of history, specialist in hygiene, skincare, haircare, and oral care) to distribute Alpecin (hair care) and Bioniq (oral care) brands throughout Brazil via the Raia and Drogasil pharmacy chain of over 3,400 physical points of sale. Dr. Wolff plans to introduce its complete product portfolio within approximately three years and aims for Brazil to become its second largest market globally.
• Yunus Negócios Sociais BrasilminorStrategic or Co-development Partner · 1 October 2023Social business partner for the Farol project, an initiative to bring health and well-being to populations in peripheral areas of Brazil. Professor Muhammad Yunus (creator of social business concept) attended the launch event in October 2023 in São Paulo's Capão Redondo neighborhood.
• MovitechminorOthers · 1 January 2023Coalition of organizations working from education to technology employability, building a strong and fair technology sector with inclusion and equity. RD Saúde became a partner in 2023. 50% of vacancies in the ninth edition were reserved for Black women and people over 50 years old.
• GPA (Grupo Pão de Açúcar)minorStrategic or Co-development PartnerJoint venture (Stix) creating a loyalty points and rewards platform, with GPA holding 66.7% participation and RD Saúde holding 33.3% participation. The JV combines retail loyalty infrastructure across both groups.
• Labi ExamesminorStrategic or Co-development PartnerJoint venture focused on laboratory exams, tests, check-ups, and vaccines, with physical units and home care service. RD Saúde holds 23.61% equity participation in Labi Exames.
• UniEdukminorOthersEducational partnership for the Pharmacy undergraduate degree program, launched by RD Saúde in partnership with UniEduk educational institution.
• EureciclominorOthersPackaging compensation entity ensuring 100% of waste from RD Saúde's own brand products in 2022 was compensated in 2023 through Eureciclo (for Caretech, Nutrigood, B-Well, Raia, Drogasil, and Natz brands).
• Reciclar pelo BrasilminorOthersPackaging compensation entity for the Needs brand, ensuring 100% of own brand packaging waste is properly compensated through Reciclar pelo Brasil.
• Green EletronminorOthersE-waste management organization for reverse logistics of electronics. Partnership enables 100% of pharmacies to serve as Voluntary Delivery Points (PEV) for batteries and small electronics, collected and properly recycled through Green Eletron.
• AbrafarmaminorOthersAssociação Brasileira de Redes de Farmácia e Drogarias (Brazilian Association of Pharmacy and Drugstore Chains), a sector industry association of which RD Saúde is a member.
• IDV (Instituto para Desenvolvimento do Varejo)minorOthersInstituto para Desenvolvimento do Varejo (Institute for Retail Development), a sector association RD Saúde participates in to contribute to broader retail industry development.

Scale indicators16 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Pague Menos: Brazilian pharmacy retail chain (PCAR3 on B3) operating ~1,600 stores across Brazil. Most direct comparable to RD Saúde in scale, footprint, and product mix, though materially smaller.
• DPSP (Drogaria São Paulo + Pacheco): Merged Brazilian pharmacy chain combining Drogaria São Paulo and Drogasil Pacheco, concentrated in São Paulo state. Directly competes with RD Saúde's Drogasil brand in Southeast Brazil.
• Panvel Farmácias: Brazilian regional pharmacy chain with strong presence in Rio Grande do Sul and growing nationally. Comparable omnichannel pharmacy retail model with own e-commerce and private-label portfolio.
• Grupo Profarma: Brazilian pharmaceutical distribution and retail group (PFRM3 on B3), now acquiring RD Saúde's 4Bio specialty pharma distribution subsidiary. Directly comparable in wholesale distribution and pharmacy retail segments.

Regional players

• Drogaria Venancio: Brazilian pharmacy chain concentrated in Rio de Janeiro, with comparable prescription and OTC retail offering. Regional competitor relevant to RD Saúde's Southeast footprint.

Broad incumbents

• CVS Health: U.S. pharmacy retail and health services giant operating 9,000+ stores plus pharmacy benefit manager (Caremark) and insurance (Aetna). Comparable omnichannel pharmacy + health-services + data strategy, though at vastly larger scale and in a different regulatory regime.
• Walgreens Boots Alliance: Global pharmacy retail platform with U.S. Walgreens and international Boots footprint. Comparable in-store health services, private-label strategy, and digital health partnerships; useful for international comparable multiples.

Emerging players

• Mercado Livre (MercadoLibre): Latin America's largest e-commerce/marketplace, including health and personal care categories in Brazil. Increasingly relevant competitor and potential marketplace/distribution partner for pharmacy retailers expanding online.

Others

• Hypera Pharma (Hyperpharma/EMS): Brazil's largest pharmaceutical manufacturer by units sold (OTC and prescription brands). Strategic supplier and competitor through proprietary OTC brands; key reference point for private-label and dermocosmetic dynamics.
• Eurofarma Laboratórios: Major Brazilian pharmaceutical manufacturer with broad generic, OTC, and specialty portfolios. Comparable adjacency in the Brazilian pharma value chain; relevant supplier to and potential partner of RD Saúde's pharmacy network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rdsaudeoficial
• Instagraminstagram.com/rdsaudeoficial

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RD Saúde